Today the Barcelona Science Park (PCB) hosts the co-session 'Science is Business', organised by Co-society–Infonomia´s innovation platform– in collaboration with the Institute for Biomedical Research (IRB Barcelona) and PCB. The aim of the conference is to present examples of 'quick' conversion of science into business and open a space for dialogue and exchange of experiences among researchers, business people and entrepreneurs to find new ways to connect science and business, and overcome the shortcomings of typical knowledge transfer mechanisms.
PCB hosts the co-session 'Science is Business, a meeting space to explore new co-innovation pathways
The president of Esquerra Republicana talks to various group leaders and is “impressed” by the level of research, and the capacity to generate and transfer knowledge and to attract talent.
This year IRB Barcelona celebrates its 10th anniversary.
The Council recognizes the impact of his research in peptide chemistry with applications in innovative therapies for cancer
The "Ciutat de Barcelona" prize represents the highest recognition that gives the city to its citizens
Antonio Zorzano heads the three-year study entitled INFLAMES, which has a budget of 679,800 euros provided by the Institute of Health Carlos III.
It is one of the three interdisciplinary projects of excellence started this year in the framework of the Spanish Biomedical Research Network (Centro de Investigación Biomédica en Red (CIBER)
The IRB Barcelona programme is aimed at students in the fourth year of their degree and is launched offering four fellowships.
The students selected will work on a research project for seven months under the supervision of a group leader.
Tens of students, from secondary school to university level, pass through IRB Barcelona each year to train in biomedicine.
The goal of «Spark» is to carry out the first preclinical stage of the development of a first-in-class drug that will prevent, stop and reverse the progression of cognitive impairment associated with schizophrenia and other mental disorders, and to be able to start first-in-humans trials by 2016
The project, which has just won a 500,000 euro endorsement from the Ministry of Economy and Finance through the “Retos-Colaboración” (Challenges-Collaboration) subprogram- will be developed by a consortium led by the biotech Iproteos -located at the Parc Cientific de Barcelona- and comprised by the company Ascil-Biopharm, IRB Barcelona, the Centre for Genomic Regulation and the University of the Basque Country
Currently there is no drug targetting the cognitive impairment associated with schizophrenia, the third most disabling disease even above paraplegia and blindness- according to the WHO and that affects about 24 million people worldwide. It is also the fifth disease with a higher annual cost to society, with more than 35,000 million euros cost only in the Europe Union
The project, led by the scientist Raquel Batlle, receives a grant of 60,000 €.
The study will determine the potential of p38 protein as a therapeutic target or as a diagnostic indicator in colorectal cancer.
On Friday 9 January in a ceremony held in Mont Sant Benet, the Catalunya la Pedrera Foundation welcomed the 172 students enrolled on one of the seven “Crazy about Science” courses, in which eight research centres in Catalonia are involved.
Forerunner of the “Crazy about Science” Programme, “Crazy about Biomedicine” enters its third year and seeks to stimulate scientific talent among secondary school students.
The project, led by Natàlia Carulla, has been awarded funds from “La Marató de TV3” initiative held in 2013.
The project, which will be undertaken over three years, aims to verify a new therapeutic target to fight Alzheimer’s.
Two Barcelona-area schools donate proceeds from their Christmas charity actions to the Institute for Research in Biomedicine.
The initiatives are a result of the campaign to raise awareness and funding that began with the launch of the IRB Barcelona dance video in October.